FET-PET Agent Approved for Glioma Imaging M. Alexander Otto, MMSc September 15, 2026

https://www.medscape.com/viewarticle/fet-pet-agent-approved-glioma-imaging-2026a1000y6x?src= The FDA has approved floretyrosine F18 (Pixclara, Telix Pharmaceuticals), an intravenous PET imaging agent, for differentiating recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and children aged 1 month or older. Floretyrosine F18 is the first floretyrosine PET (FET-PET) agent approved in the US for glioma, Telix said in a press release.